First CAR-T trial launches for aggressive MS
NCT ID NCT07139743
Summary
This is an early-stage safety study testing a new cell therapy called obe-cel in adults with a progressive form of multiple sclerosis that hasn't responded to other treatments. The main goal is to see if the treatment is safe and what side effects it might cause, while also looking for early signs that it could help slow the disease. Participants will receive a single infusion of the therapy after preparatory chemotherapy and will be closely monitored for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrooke's Hospital
RECRUITINGCambridge, United Kingdom
Contact
-
Hospital Universitari i Politecnic La Fe de Valencia
RECRUITINGValencia, Spain
Contact
-
Hospital Universitario Vall d'Hebron - PPDS
ACTIVE_NOT_RECRUITINGBarcelona, Spain
-
Royal Hallamshire Hospital
RECRUITINGSheffield, United Kingdom
Contact
-
Stanford University
NOT_YET_RECRUITINGRedwood City, California, 94063, United States
Contact
-
The National Hospital for Neurology & Neurosurgery
RECRUITINGLondon, United Kingdom
Contact Email: •••••@•••••
Contact
-
Western General Hospital Edinburgh - PPDSE Edinburgh
RECRUITINGEdinburgh, United Kingdom
Contact
Conditions
Explore the condition pages connected to this study.